Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00126230 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Trial of Docetaxel-samarium in Patients With Hormone-refractory Advanced Prostate Cancer

StatusTerminated
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study Identification, Study Status, Sponsor/Collaborators, Oversight, Referencesv4
  2. Trial status: Recruiting to Terminated Site details revisedv3 Show 1 more changeShow less
    • Site details revised
  3. Interventions: Docetaxel, samarium (Drug) to docetaxel and samarium (Drug) Secondary endpoints revised (3) · Site contact updated · Eligibility criteria expanded, about 1 word · 1 morev2 Show 4 more changesShow less
    • Secondary endpoints revised (3)
    • Site contact updated
    • Eligibility criteria expanded, about 1 word
    • Study title shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a prospective phase II trial of docetaxel-samarium in patients with hormone-refractory advanced prostate cancer who achieve a response or a stabilization to docetaxel-estramustine.
Trial Details
NCT Number NCT00126230
Lead Sponsor Gustave Roussy, Cancer Campus, Grand Paris
Conditions Prostate Cancer
Enrollment 55 participants
Start Date
Updated on ClinicalTrials.gov